KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Emergent BioSolutions (EBS) Shares Outstanding (2016 - 2026)

Emergent BioSolutions has reported Shares Outstanding over the past 17 years, most recently at $61.4 million for Q1 2026.

  • For Q1 2026, Shares Outstanding rose 2.16% year-over-year to $61.4 million; the TTM value through Mar 2026 reached $61.4 million, up 2.16%, while the annual FY2025 figure was $60.9 million, 1.67% up from the prior year.
  • Shares Outstanding for Q1 2026 was $61.4 million at Emergent BioSolutions, up from $60.9 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $61.4 million in Q1 2026 and troughed at $52.7 million in Q3 2025.
  • A 5-year average of $57.8 million and a median of $57.8 million in 2023 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: grew 0.91% in 2022 and later rose 4.01% in 2024.
  • Year by year, Shares Outstanding stood at $55.7 million in 2022, then increased by 3.77% to $57.8 million in 2023, then grew by 3.63% to $59.9 million in 2024, then increased by 1.67% to $60.9 million in 2025, then increased by 0.82% to $61.4 million in 2026.
  • Business Quant data shows Shares Outstanding for EBS at $61.4 million in Q1 2026, $60.9 million in Q4 2025, and $60.6 million in Q3 2025.